DH
Therapeutic Areas
Greenwich LifeSciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| GLSI-100 (GP2 + GM-CSF) | Prevention of recurrence in HLA-A*02 positive, HER2/neu positive breast cancer (adjuvant setting) | Phase 3 |
Leadership Team at Greenwich LifeSciences
DM
Dr. Mothaffar F. Rimawi
Steering Committee Member, Baylor College of Medicine
DF
Dr. Francois-Clement Bidard
Steering Committee Member, Unicancer (France)
DW
Dr. William J. Gradishar
Steering Committee Member, Northwestern University
DS
Dr. Sibylle Loibl
Steering Committee Member, German Breast Group (GBG)
DM
Dr. Miguel Martin
Steering Committee Member, GEICAM (Spain)
DJ
Dr. Joyce A. O’Shaughnessy
Steering Committee Member, US Oncology
DL
Dr. Laura M. Spring
Steering Committee Member, Harvard Medical School/Dana-Farber
DC
Dr. Cesar A. Santa-Maria
Steering Committee Member, Johns Hopkins University
S
Snehal
Author/Website Contact